secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cytek Biosciences, Inc. (CTKB)
CIK:        0001831915
Form:       8-K
Filed at:   2023-05-09T23:59:59+00:00
Accession:  0001193125-23-139445
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cytek Q1 revenue $37.1M (+6% YoY); net loss widens to $6.8M; organic revenue -4%; revises FY23 outlook to $205-220M
--------------------------------------------------------------------------------

- Total revenue $37.1M, up 6% YoY; constant-currency revenue $38.1M (+9%).
- Organic revenue (ex-Luminex) $33.7M, down 4% YoY; U.S. pharma/biotech weakness cited.
- Net loss $6.8M vs $2.2M loss in Q1 2022; adjusted EBITDA -$2.5M vs +$1.9M.
- Completed Luminex flow cytometry asset acquisition for $44.9M on Feb 28, 2023; contributed $3.4M revenue.
- Revised FY2023 revenue guidance to $205-220M (25-34% growth), citing macro uncertainties and longer sales cycles.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831915/000119312523139445/0001193125-23-139445-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831915/000119312523139445/d468414d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-139445

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer